✦ LIBER ✦

Development of a novel viral DNA vaccine against human papillomavirus: AcHERV-HP16L1

✍ Scribed by Hee-Jung Lee; Nuri Park; Hee-Jeong Cho; Jong Kwang Yoon; Nguyen Dinh Van; Yu-Kyoung Oh; Young Bong Kim

Book ID: 116962266
Publisher: Elsevier Science
Year: 2010
Tongue: English
Weight: 648 KB
Volume: 28
Category: Article
ISSN: 0264-410X
DOI: 10.1016/j.vaccine.2009.11.044

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Maltosylated polyethylenimine-based trip

Maltosylated polyethylenimine-based triple nanocomplexes of human papillomavirus 16L1 protein and DNA as a vaccine co-delivery system

✍ Hee-Jeong Cho; Su-Eun Han; Saewon Im; Young Lee; Young Bong Kim; Taehoon Chun; Y 📂 Article 📅 2011 🏛 Elsevier Science 🌐 English ⚖ 828 KB

Antibody-dependent enhancement of viral

Antibody-dependent enhancement of viral infectivity: III. Relation to the development of a vaccine against human immunodeficiency virus

✍ David C. Montefiori; W. Edward Robinson Jr; William M. Mitchell 📂 Article 📅 1988 🏛 Elsevier Science ⚖ 229 KB

Sustained efficacy up to 4·5 years of a

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

✍ Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barb 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 134 KB

Sustained efficacy up to 4·5 years of a

Sustained efficacy up to 4·5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial

✍ Diane M Harper; Eduardo L Franco; Cosette M Wheeler; Anna-Barbara Moscicki; Barb 📂 Article 📅 2006 🏛 The Lancet 🌐 English ⚖ 134 KB

## Background: Effective vaccination against hpv 16 and hpv 18 to prevent cervical cancer will require a high level of sustained protection against infection and precancerous lesions. our aim was to assess the long-term efficacy, immunogenicity, and safety of a bivalent hpv-16/18 l1 virus-like part

Efficacy of a quadrivalent prophylactic

Efficacy of a quadrivalent prophylactic human papillomavirus (types 6, 11, 16, and 18) L1 virus-like-particle vaccine against high-grade vulval and vaginal lesions: a combined analysis of three randomised clinical trials

✍ Elmar A Joura; Sepp Leodolter; Mauricio Hernandez-Avila; Cosette M Wheeler; Gonz 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 165 KB

Efficacy of a prophylactic adjuvanted bi

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial

✍ Jorma Paavonen; David Jenkins; F Xavier Bosch; Paulo Naud; Jorge Salmerón; Coset 📂 Article 📅 2007 🏛 The Lancet 🌐 English ⚖ 151 KB